Results 171 to 180 of about 54,096 (328)
Primary and Secondary Myelofibrosis: Its Relationship to "PNH-like Defect" [PDF]
, 1972 Chi-yen Kuo +2 more
openalex +1 more source
American Journal of Hematology, Volume 100, Issue S4, Page 5-15, June 2025.ABSTRACT With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importance. This review focuses on the early recognition of myeloid disorders, especially chronic myeloid disorders,
Daniel A. Arber, Attilio Orazi
wiley +1 more source
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
American Journal of Hematology, Volume 100, Issue S4, Page 30-50, June 2025.ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +1 more source
The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis [PDF]
, 1985 Jonathan Miller +3 more
openalex +1 more source
American Journal of Hematology, Volume 100, Issue S4, Page 16-29, June 2025.ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley +1 more source
Immunologic abnormalities in myelofibrosis with activation of the complement system [PDF]
, 1981 BR Gordon, M Coleman, P Kohen, N K Day
openalex +1 more source
Topics of Interest in Women With Myeloproliferative Neoplasms
American Journal of Hematology, Volume 100, Issue S4, Page 74-87, June 2025.Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber +2 more
wiley +1 more source
Localized Tuberculosis and Myelofibrosis with Myeloid Metaplasia : An extremely unusual presentation [PDF]
, 1996 Myelofibrosis with myeloid metaplasia (MMM) is usually considered primary agnogenic, however, it may be secondary to various diseases, The association of tuberculosis with MMIM is exceedingly rare, however, the pathogenetic relationship between the two ...
Muzaffar, Suhail
core +1 more source
Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib
Clinical Case Reports, Volume 13, Issue 6, June 2025.ABSTRACT We present a woman with severe refractory livedoid vasculopathy who was successfully treated with tofacitinib (5 mg twice a day). The ulcers gradually healed over a period of 2–3 months without experiencing any adverse events over a 1‐year follow‐up period.
Parvin Mansouri, Nikoo Mozafari
wiley +1 more source
PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [PDF]
, 1989 Giovanni Barosi
openalex +1 more source